Vistagen (NASDAQ:VTGN) has reported new preclinical data supporting the potential antidepressant activity of its Itruvone nasal spray. The study showed that the spray binds to receptors of peripheral chemosensory neurons in the nasal cavity, limiting transport of molecules to the circulatory system and minimizing potential systemic exposure. The company believes this could change the treatment paradigm for depression disorders. Vistagen recently reported that Itruvone is now staged for potential Phase 2B clinical development in the U.S. as a stand-alone treatment for major depressive disorder (MDD).